These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Pharmacodynamics and pharmacokinetics of 2 glibenclamide preparations in type 2 diabetes. Intraindividual double-blind comparison of Euglucon 5 (HB 419) and Euglucon N (HB 420)].
    Author: Haupt E, Putschky F, Zoltobrocki M, Schöffling K.
    Journal: Dtsch Med Wochenschr; 1984 Feb 10; 109(6):210-3. PubMed ID: 6421561.
    Abstract:
    A new galenic form of glibenclamide (with a higher specific surface area for better absorption) was compared with the conventional form in 12 insulin-dependent and glibenclamide-treated diabetics (three women, nine men; aged 37-60 years) in a double-blind controlled crossover study. There was more rapid absorption, with a maximal serum concentration after 1 1/2 hours, compared with the usual preparation which gave a lower longer-sustained maximum of serum-glibenclamide level between 1 1/2 and 4 hours. In addition, there was more complete absorption so that the needed daily dose was decreased: 3.5 mg of the new form was bio-equivalent to 5 mg of the ordinary form. Duration of effect of the new form was not shorter despite different pharmacokinetics. Response of serum insulin and C-peptide level was the same in the two forms. On the other hand, the blood-glucose profile was significantly better with the new form.
    [Abstract] [Full Text] [Related] [New Search]